The Japanese guidelines for the management of sepsis

Shigeto Oda, Mayuki Aibiki, Toshiaki Ikeda, Hitoshi Imaizumi, Shigeatsu Endo, Ryoichi Ochiai, Joji Kotani, Nobuaki Shime, Osamu Nishida, Takayuki Noguchi, Naoyuki Matsuda, Hiroyuki Hirasawa, Sepsis Registry Committee of The Japanese Society of Intensive Care Medicine, Shigeto Oda, Mayuki Aibiki, Toshiaki Ikeda, Hitoshi Imaizumi, Shigeatsu Endo, Ryoichi Ochiai, Joji Kotani, Nobuaki Shime, Osamu Nishida, Takayuki Noguchi, Naoyuki Matsuda, Hiroyuki Hirasawa, Sepsis Registry Committee of The Japanese Society of Intensive Care Medicine

Abstract

This is a guideline for the management of sepsis, developed by the Sepsis Registry Committee of The Japanese Society of Intensive Care Medicine (JSICM) launched in March 2007. This guideline was developed on the basis of evidence-based medicine and focuses on unique treatments in Japan that have not been included in the Surviving Sepsis Campaign guidelines (SSCG), as well as treatments that are viewed differently in Japan and in Western countries. Although the methods in this guideline conform to the 2008 SSCG, the Japanese literature and the results of the Sepsis Registry Survey, which was performed twice by the Sepsis Registry Committee in intensive care units (ICUs) registered with JSICM, are also referred. This is the first and original guideline for sepsis in Japan and is expected to be properly used in daily clinical practice. This article is translated from Japanese, originally published as "The Japanese Guidelines for the Management of Sepsis" in the Journal of the Japanese Society of Intensive Care Medicine (J Jpn Soc Intensive Care Med), 2013; 20:124-73. The original work is at http://dx.doi.org/10.3918/jsicm.20.124.

References

    1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving sepsis campaign management guidelines committee: surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–872. doi: 10.1097/01.CCM.0000117317.18092.E4.
    1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327. doi: 10.1097/01.CCM.0000298158.12101.41.
    1. Hirasawa H. On the revised version of Surviving Sepsis Campaign (SSC) Guidelines. J Jpn Soc Surg Infect. 2008;5:301–311.
    1. Hirasawa H, Oda S, Nakamura M. Points of issues on surviving sepsis campaign guidelines from the Japanese viewpoints. Jpn J Surg Metab Nutr. 2009;43:161–165.
    1. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010;38:S534–S538. doi: 10.1097/CCM.0b013e3181f208ac.
    1. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med. 1997;25:372–374. doi: 10.1097/00003246-199702000-00029.
    1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer T, Varonen H, Vist GE, Williams JW, Jr, Zaza S. GRADE Working Group: grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490–1498. doi: 10.1136/bmj.328.7454.1490.
    1. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129:174–181. doi: 10.1378/chest.129.1.174.
    1. Nutritional management guideline for acute respiratory failure patients with ventilatory supportJpn J Respir Care 2012, 29: 75-120.
    1. Bone RC, Fisher CJ, Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1989;17:389–393. doi: 10.1097/00003246-198905000-00002.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsisCrit Care Med 1992, 20: 864-874.
    1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–1256. doi: 10.1097/01.CCM.0000050454.01978.3B.
    1. Weiss M, Huber-Lang M, Taenzer M, Traeger K, Altherr J, Kron M, Hay B, Schneider M. Different patient case mix by applying the 2003 SCCM/ESICM/ACCP/ATS/SIS sepsis definitions instead of the 1992 ACCP/SCCM sepsis definitions in surgical patients: a retrospective observational study. BMC Med Inform Decis Mak. 2009;9:25. doi: 10.1186/1472-6947-9-25.
    1. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140. doi: 10.1016/0196-6553(88)90053-3.
    1. Calandra T, Cohen J. International Sepsis Forum Definition of Infection in the ICU Consensus Conference: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538–1548. doi: 10.1097/01.CCM.0000168253.91200.83.
    1. Moreno RP, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz PG. SAPS 3 Investigators: Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med. 2008;34:496–504. doi: 10.1007/s00134-007-0943-1.
    1. Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M, Cal RG, de Sousa EF, Abe TP, de Andrade J, de Matos JD, Rezende E, Assunção M, Avezum A, Rocha PC, de Matos GF, Bento AM, Corrêa AD, Vieira PC, Knobel E. Brazilian Sepsis Epidemiological Study: Brazilian Sepsis Epidemiological Study (BASES study) Crit Care. 2004;8:R251–R260. doi: 10.1186/cc2892.
    1. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638–1652. doi: 10.1097/00003246-199510000-00007.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ., Jr Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001.
    1. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisones on mortality in patients with septic shock. JAMA. 2002;288:862–871. doi: 10.1001/jama.288.7.862.
    1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15. doi: 10.1186/cc8872.
    1. Van den Bruel A, Thompson MJ, Haj-Hassan T, Stevens R, Moll H, Lakhanpaul M, Mant D. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ. 2011;342:d3082. doi: 10.1136/bmj.d3082.
    1. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine. 2005;29:169–175. doi: 10.1016/j.cyto.2004.10.010.
    1. Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y, Shinozaki K, Hirasawa H. Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Crit Care. 2010;14:R27. doi: 10.1186/cc8898.
    1. Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem. 2008;15:581–587. doi: 10.2174/092986708783769704.
    1. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31:1737–1741. doi: 10.1097/01.CCM.0000063440.19188.ED.
    1. Tang BMP, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007;7:210–217. doi: 10.1016/S1473-3099(07)70052-X.
    1. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527–534. doi: 10.1086/422254.
    1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA. 1995;273:117–123. doi: 10.1001/jama.1995.03520260039030.
    1. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stéphan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132:621–630. doi: 10.7326/0003-4819-132-8-200004180-00004.
    1. A randomized trial of diagnostic techniques for ventilator-associated pneumoniaN Engl J Med 2006, 355: 2619-2630.
    1. Berton DC, Kalil AC, Cavalcanti M, Teixeira PJ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev. 2008;4:CD006482.
    1. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45. doi: 10.1086/599376.
    1. Caldeira D, David C, Sampaio C. Skin antiseptics in venous puncture-site disinfection for prevention of blood culture contamination: systematic review with meta-analysis. J Hosp Infect. 2011;77:223–232. doi: 10.1016/j.jhin.2010.10.015.
    1. Mimoz O, Karim A, Mercat A, Cosseron M, Falissard B, Parker F, Richard C, Samii K, Nordmann P. Chlorhexidine compared with povidone-iodine as skin preparation before blood culture. A randomized, controlled trial. Ann Intern Med. 1999;131:834–837. doi: 10.7326/0003-4819-131-11-199912070-00006.
    1. Suwanpimolkul G, Pongkumpai M, Suankratay C. A randomized trial of 2% chlorhexidine tincture compared with 10% aqueous povidone-iodine for venipuncture site disinfection: effects on blood culture contamination rates. J Infect. 2008;56:354–359. doi: 10.1016/j.jinf.2008.03.001.
    1. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394–e434. doi: 10.1161/CIRCULATIONAHA.105.165564.
    1. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol. 2007;45:3546–3548. doi: 10.1128/JCM.01555-07.
    1. Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med. 1993;119:270–272. doi: 10.7326/0003-4819-119-4-199308150-00003.
    1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329. doi: 10.1001/jama.2009.1754.
    1. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136:1237–1248. doi: 10.1378/chest.09-0087.
    1. 2007 JSICM Sepsis 1st Registry: management of severe sepsis and septic shock in JapanJ Jpn Soc Intensive Care Med 2013, 20: 329-334. in Japanese
    1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596. doi: 10.1097/01.CCM.0000217961.75225.E9.
    1. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645. doi: 10.1128/AAC.49.9.3640-3645.2005.
    1. Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Horton JM, Studnek JR, Kline JA, Jones AE. Emergency Medicine Shock Research Network (EMSHOCKNET): Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med. 2011;39:2066–2071. doi: 10.1097/CCM.0b013e31821e87ab.
    1. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009;180:861–866. doi: 10.1164/rccm.200812-1912OC.
    1. Gaieski DF, Mikkelsen ME, Band RA, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–1053. doi: 10.1097/CCM.0b013e3181cc4824.
    1. Erbay A, Idil A, Gözel MG, Mumcuoğlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34:575–579. doi: 10.1016/j.ijantimicag.2009.07.006.
    1. Garnacho-Montero J, Garcia-Cabrera E, Diaz-Martin A, Lepe-Jiménez JA, Iraurgi-Arcarazo P, Jiménez-Alvarez R, Revuelto-Rey J, Aznar-Martín J. Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis. 2010;42:185–192. doi: 10.3109/00365540903418522.
    1. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Eur Surveill. 2008;13:47.
    1. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008) Diagn Microbiol Infect Dis. 2009;65:414–426. doi: 10.1016/j.diagmicrobio.2009.08.020.
    1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumoniaAm J Respir Crit Care Med 2005, 171: 388-416.
    1. Paul M, Shani V, Muchter E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy. Antimicrob Agent Chemother. 2010;4:4851–4863. doi: 10.1128/AAC.00627-10.
    1. Paul M, Kariv G, Goldberg E, Raskin M, Raskin M, Shaked H, Hazzan R, Samra Z, Paghis D, Bishara J, Leibovici L. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658–2665. doi: 10.1093/jac/dkq373.
    1. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis. 2011;53:177–184. doi: 10.1093/cid/cir323.
    1. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012;307:2390–2399. doi: 10.1001/jama.2012.5833.
    1. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010;38:1651–1664. doi: 10.1097/CCM.0b013e3181e96b91.
    1. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, Kollef MH. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742–1748. doi: 10.1128/AAC.01365-09.
    1. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, Ramirez JA. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis. 2011;11:181–189. doi: 10.1016/S1473-3099(10)70314-5.
    1. Schuster MG, Edwards JE, Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83–90. doi: 10.7326/0003-4819-149-2-200807150-00004.
    1. Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Nurs Clin North Am. 2011;23:79–97. doi: 10.1016/j.ccell.2010.12.005.
    1. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362:1804–1813. doi: 10.1056/NEJMra0904124.
    1. Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, Tsuchida T, Uchino M, Ikeuchi H. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011;17:52–57. doi: 10.1007/s10156-010-0086-0.
    1. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC =2 mg/L, by the broth microdilution method. BMC Infect Dis. 2010;10:159. doi: 10.1186/1471-2334-10-159.
    1. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200. doi: 10.1086/524667.
    1. Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, Corey GR, Abrutyn E. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008;62:1413–1421. doi: 10.1093/jac/dkn372.
    1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681. doi: 10.1086/420818.
    1. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, Niki Y, Watanabe S, Furue M, Ito T, Croos-Dabrera R, Tack KJ. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60:1361–1369. doi: 10.1093/jac/dkm369.
    1. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35:3–12. doi: 10.1016/j.ijantimicag.2009.09.013.
    1. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin. 2010;26:407–421. doi: 10.1185/03007990903454912.
    1. Logman JF, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A, van Hout BA. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin. 2010;26:1565–1578. doi: 10.1185/03007995.2010.481251.
    1. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010;38:1802–1808. doi: 10.1097/CCM.0b013e3181eb3b96.
    1. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011;139:1148–1155. doi: 10.1378/chest.10-1556.
    1. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–629. doi: 10.1093/cid/cir895.
    1. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–351. doi: 10.1016/j.ijantimicag.2007.12.009.
    1. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis–bolus versus continuous administration? Crit Care Med. 2009;37:926–933. doi: 10.1097/CCM.0b013e3181968e44.
    1. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–150. doi: 10.1093/jac/dkp139.
    1. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840–851. doi: 10.1097/CCM.0b013e3181961bff.
    1. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med. 2009;37:2071–2078. doi: 10.1097/CCM.0b013e3181a0054d.
    1. Gomez Silva BN, Andriolo RB, Atallah ÁN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Syst Rev. 2010;12:CD007934.
    1. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004;125:1791–1799. doi: 10.1378/chest.125.5.1791.
    1. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66:1343–1348. doi: 10.1097/TA.0b013e31819dca4e.
    1. Giantsou E, Liratzopoulos N, Efraimidou E, Leeper KV, Anzueto A, Benz-Scott L, Rodino FJ. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129:1210–1218. doi: 10.1378/chest.129.5.1210.
    1. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011;39:319–325. doi: 10.1007/s15010-011-0116-6.
    1. Morel J, Casoetto J, Jospé R, Aubert G, Terrana R, Dumont A, Molliex S, Auboyer C. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010;14:R225. doi: 10.1186/cc9373.
    1. Kartali-Ktenidou S, Manolas K. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med. 2007;33:1533–1540. doi: 10.1007/s00134-007-0619-x.
    1. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52:1232–1240. doi: 10.1093/cid/cir063.
    1. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–1066. doi: 10.1001/jama.2009.1297.
    1. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463–474. doi: 10.1016/S0140-6736(09)61879-1.
    1. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177:498–505. doi: 10.1164/rccm.200708-1238OC.
    1. De Waele JJ. Early source control in sepsis. Langenbecks Arch Surg. 2010;395:489–494. doi: 10.1007/s00423-010-0650-1.
    1. Kumar A, Kazmi M, Ronald J, Seleman M, Roberts D, Gurka D, Wood K, Suppes R, Feinstein D, Taiberg L, Zanotti S, Parrillo J, Dellinger P. Rapidity of source control implementation following onset of hypotension is a determinant of survival in human septic shock [abstract] Crit Care Med. 2004;32(12):A158. doi: 10.1097/00003246-200412001-00560.
    1. Janzen DL, Padley SP, Adler BD, Müller NL. Acute pulmonary complications in immunocompromised non-AIDS patients: comparison of diagnostic accuracy of CT and chest radiography. Clin Radiol. 1993;47:159–165. doi: 10.1016/S0009-9260(05)81153-5.
    1. Boiselle PM, Crans CA, Jr, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol. 1999;172:1301–1309. doi: 10.2214/ajr.172.5.10227507.
    1. Chang KH, Han MH, Roh JK, Kim IO, Han MC, Kim CW. Gd-DTPA-enhanced MR imaging of the brain in patients with meningitis: comparison with CT. AJR Am J Roentgenol. 1990;154:809–816. doi: 10.2214/ajr.154.4.2107681.
    1. Erdman WA, Tamburro F, Jayson HT, Weatherall PT, Ferry KB, Peshock RM. Osteomyelitis: characteristics and pitfalls of diagnosis with MR imaging. Radiology. 1991;180:533–539. doi: 10.1148/radiology.180.2.2068324.
    1. Muñoz A, Castillo M, Melchor MA, Gutiérrez R. Acute neck infections: prospective comparison between CT and MRI in 47 patients. J Comput Assist Tomogr. 2001;25:733–741. doi: 10.1097/00004728-200109000-00011.
    1. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol. 2010;12:335–342. doi: 10.1007/s11307-009-0268-2.
    1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655. doi: 10.1378/chest.101.6.1644.
    1. Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, Meduri GU, Moreno RP, Putensen C, Stewart T, Torres A. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27–28 April 2006. Intensive Care Med. 2007;33:575–590. doi: 10.1007/s00134-007-0531-4.
    1. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, Tomlanovich MC. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004;32:1637–1642. doi: 10.1097/01.CCM.0000132904.35713.A7.
    1. Mikkelsen ME, Miltiades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, Bellamy SL, Christie JD. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009;37:1670–1677. doi: 10.1097/CCM.0b013e31819fcf68.
    1. Nguyen HB, Loomba M, Yang JJ, Jacobsen G, Shah K, Otero RM, Suarez A, Parekh H, Jaehne A, Rivers EP. Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. J Inflamm (Lond) 2010;7:6. doi: 10.1186/1476-9255-7-6.
    1. Jansen TC, van Bommel J, Mulder PG, Lima AP, van der Hoven B, Rommes JH, Snellen FT, Bakker J. Prognostic value of blood lactate levels: does the clinical diagnosis at admission matter? J Trauma. 2009;66:377–385. doi: 10.1097/TA.0b013e3181648e2f.
    1. van Beest PA, Hofstra JJ, Schultz MJ, Boerma EC, Spronk PE, Kuiper MA. The incidence of low venous oxygen saturation on admission to the intensive care unit: a multi-center observational study in The Netherlands. Crit Care. 2008;12:R33. doi: 10.1186/cc6811.
    1. Hernandez G, Peña H, Cornejo R, Rovegno M, Retamal J, Navarro JL, Aranguiz I, Castro R, Bruhn A. Impact of emergency intubation on central venous oxygen saturation in critically ill patients: a multicenter observational study. Crit Care. 2009;13:R63. doi: 10.1186/cc7802.
    1. Maciel AT, Noritomi DT, Park M. Metabolic acidosis in sepsis. Endocr Metab Immune Disord Drug Targets. 2010;10:252–257. doi: 10.2174/187153010791936900.
    1. Sivayoham N, Rhodes A, Jaiganesh T, van Zyl SN, Elkhodhair S, Krishnanandan Outcomes from implementing early goal-directed therapy for severe sepsis and septic shock: a 4-year observational cohort study. Eur J Emerg Med. 2012;19:235–240. doi: 10.1097/MEJ.0b013e32834bbea6.
    1. Puskarich MA, Marchick MR, Kline JA, Steuerwald MT, Jones AE. One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study. Crit Care. 2009;13:R167. doi: 10.1186/cc8138.
    1. Murphy CV, Schramm GE, Doherty JA, Reichley RM, Gajic O, Afessa B, Micek ST, Kollef MH. The importance of fluid management in acute lung injury secondary to septic shock. Chest. 2009;136:102–109. doi: 10.1378/chest.08-2706.
    1. Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, Parrillo JE, Dellinger RP, Trzeciak S. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock. 2009;32:35–39. doi: 10.1097/SHK.0b013e3181971d47.
    1. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303:739–746. doi: 10.1001/jama.2010.158.
    1. Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182:752–761. doi: 10.1164/rccm.200912-1918OC.
    1. McLean AS, Huang SJ, Kot M, Rajamani A, Hoyling L. Comparison of cardiac output measurements in critically ill patients: FloTrac/Vigileo vs transthoracic Doppler echocardiography. Anaesth Intensive Care. 2011;39:590–598.
    1. Monnet X, Jabot J, Maizel J, Richard C, Teboul JL. Norepinephrine increases cardiac preload and reduces preload dependency assessed by passive leg raising in septic shock patients. Crit Care Med. 2011;39:689–694. doi: 10.1097/CCM.0b013e318206d2a3.
    1. Mousavi N, Czarnecki A, Ahmadie R, Tielan F, Kumar K, Lytwyn M, Kumar A, Jassal DS. The utility of tissue Doppler imaging for the noninvasive determination of left ventricular filling pressures in patients with septic shock. J Intensive Care Med. 2010;25:163–167. doi: 10.1177/0885066609359903.
    1. Griffee MJ, Merkel MJ, Wei KS. The role of echocardiography in hemodynamic assessment of septic shock. Crit Care Clin. 2010;26:365–382. doi: 10.1016/j.ccc.2010.01.001.
    1. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256. doi: 10.1056/NEJMoa040232.
    1. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011;37:86–96. doi: 10.1007/s00134-010-2081-4.
    1. Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227–234. doi: 10.1097/00003246-200102000-00001.
    1. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887. doi: 10.1056/NEJMoa067373.
    1. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med. 2009;37:811–818. doi: 10.1097/CCM.0b013e3181961ace.
    1. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–582. doi: 10.1097/00000542-200203000-00011.
    1. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279–1282. doi: 10.1097/00003246-199708000-00012.
    1. Malay MB, Ashton RC, Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47:699–703. doi: 10.1097/00005373-199910000-00014.
    1. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779–789. doi: 10.1056/NEJMoa0907118.
    1. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med. 2012;40:725–730. doi: 10.1097/CCM.0b013e31823778ee.
    1. Cariou A, Pinsky MR, Monchi M, Laurent I, Vinsonneau C, Chiche JD, Charpentier J, Dhainaut JF. Is myocardial adrenergic responsiveness depressed in human septic shock? Intensive Care Med. 2008;34:917–922. doi: 10.1007/s00134-008-1022-y.
    1. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med. 2007;35:1599–1608. doi: 10.1097/01.CCM.0000266683.64081.02.
    1. Schmittinger CA, Dünser MW, Haller M, Ulmer H, Luckner G, Torgersen C, Jochberger S, Hasibeder WR. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care. 2008;12:R99. doi: 10.1186/cc6976.
    1. Heinz G, Geppert A, Delle Karth G, Reinelt P, Gschwandtner ME, Neunteufl T, Zauner C, Frossard M, Siostrzonek P. IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure. Intensive Care Med. 1999;25:620–624. doi: 10.1007/s001340050913.
    1. Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Landoni G, Pelaia P, Pietropaoli P, Van Aken H, Teboul JL, Ince C, Westphal M. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care. 2010;14:R232. doi: 10.1186/cc9387.
    1. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34:2226–2234. doi: 10.1007/s00134-008-1219-0.
    1. Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Heffner AC, Kline JA, Jones AE. Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation. Acad Emerg Med. 2012;19:252–258. doi: 10.1111/j.1553-2712.2012.01292.x.
    1. Hernandez G, Regueira T, Bruhn A, Castro R, Rovegno M, Fuentealba A, Veas E, Berrutti D, Florez J, Kattan E, Martin C, Ince C. Relationship of systemic, hepatosplanchnic, and microcirculatory perfusion parameters with 6-hour lactate clearance in hyperdynamic septic shock patients: an acute, clinical-physiological, pilot study. Ann Intensive Care. 2012;2:44. doi: 10.1186/2110-5820-2-44.
    1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–1693. doi: 10.1056/NEJMoa050333.
    1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824. doi: 10.1164/ajrccm.149.3.7509706.
    1. Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–2533.
    1. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338:347–354. doi: 10.1056/NEJM199802053380602.
    1. Brochard L, Roudot-Thoraval F, Roupie E, Delclaux C, Chastre J, Fernandez-Mondéjar E, Clémenti E, Mancebo J, Factor P, Matamis D, Ranieri M, Blanch L, Rodi G, Mentec H, Dreyfuss D, Ferrer M, Brun-Buisson C, Tobin M, Lemaire F. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. Am J Respir Crit Care Med. 1998;158:1831–1838. doi: 10.1164/ajrccm.158.6.9801044.
    1. Brower RG, Shanholtz CB, Fessler HE, Shade DM, White P, Jr, Wiener CM, Teeter JG, Dodd-o JM, Almog Y, Piantadosi S. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med. 1999;27:1492–1498. doi: 10.1097/00003246-199908000-00015.
    1. Stewart TE, Meade MO, Cook DJ, Granton JT, Hodder RV, Lapinsky SE, Mazer CD, McLean RF, Rogovein TS, Schouten BD, Todd TR, Slutsky AS. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med. 1998;338:355–361. doi: 10.1056/NEJM199802053380603.
    1. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndromeN Engl J Med 2000, 342: 1301-1308.
    1. Checkley W, Brower R, Korpak A, Thompson BT. Effect of a clinical trial on mechanical ventilation practices in patients with acute lung injury. Am J Respr Crit Care Med. 2008;177:1215–1222. doi: 10.1164/rccm.200709-1424OC.
    1. Ferguson ND, Frutos-Vivar F, Esteban A, Anzueto A, Alía I, Brower RG, Stewart TE, Apezteguía C, González M, Soto L, Abroug F, Brochard L. Airway pressures, tidal volumes, and mortality in patients with acute respiratory distress syndrome. Crit Care Med. 2005;33:21–30. doi: 10.1097/01.CCM.0000150652.91411.66.
    1. Eichacker PQ, Gerstenberger EP, Banks SM, Cui X, Natanson C. Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respr Crit Care Med. 2002;166:1510–1514. doi: 10.1164/rccm.200208-956OC.
    1. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008;299:637–645. doi: 10.1001/jama.299.6.637.
    1. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008;299:646–655. doi: 10.1001/jama.299.6.646.
    1. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327–336. doi: 10.1056/NEJMoa032193.
    1. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS, Pullenayegum E, Zhou Q, Cook D, Brochard L, Richard JC, Lamontagne F, Bhatnagar N, Stewart TE, Guyatt G. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010;303:865–873. doi: 10.1001/jama.2010.218.
    1. Oba Y, Thameem DM, Zaza T. High levels of PEEP may improve survival in acute respiratory distress syndrome: a meta-analysis. Respir Med. 2009;103:1174–1181. doi: 10.1016/j.rmed.2009.02.008.
    1. Phoenix SI, Paravastu S, Columb M, Vincent JL, Nirmalan M. Does a higher positive end expiratory pressure decrease mortality in acute respiratory distress syndrome? A systematic review and meta-analysis. Anesthesiology. 2009;110:1098–1105. doi: 10.1097/ALN.0b013e31819fae06.
    1. Putensen C, Theuerkauf N, Zinserling J, Wrigge H, Pelosi P. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med. 2009;151:566–576. doi: 10.7326/0003-4819-151-8-200910200-00011.
    1. Carvalho AR, Jandre FC, Pino AV, Bozza FA, Salluh J, Rodrigues R, Ascoli FO, Giannella-Neto A. Positive end-expiratory pressure at minimal respiratory elastance represents the best compromise between mechanical stress and lung aeration in oleic acid induced lung injury. Crit Care. 2007;11:R86. doi: 10.1186/cc6093.
    1. Ward NS, Lin DY, Nelson DL, Bozza FA, Salluh J, Rodrigues R, Ascoli FO, Giannella-Neto A. Successful determination of lower inflection point and maximal compliance in a population of patients with acute respiratory distress syndrome. Crit Care Med. 2002;30:963–968. doi: 10.1097/00003246-200205000-00002.
    1. Britos M, Smoot E, Liu KD, Thompson BT, Checkley W, Brower RG. The value of positive end-expiratory pressure and FiO2 criteria in the definition of the acute respiratory distress syndrome. Crit Care Med. 2011;39:2025–2030. doi: 10.1097/CCM.0b013e31821cb774.
    1. Bryan AC. Conference on the scientific basis of respiratory therapy. Pulmonary physiotherapy in the pediatric age group. Comments of a devil’s advocate. Am Rev Respir Dis. 1974;110:143–144.
    1. Gattinoni L, Pelosi P, Vitale G, Pesenti A, D'Andrea L, Mascheroni D. Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure. Anesthesiology. 1991;74:15–23. doi: 10.1097/00000542-199101000-00004.
    1. Pappert D, Rossaint R, Slama K, Grüning T, Falke KJ. Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. Chest. 1994;106:1511–1516. doi: 10.1378/chest.106.5.1511.
    1. Gillart T, Bazin JE, Guelon D, Constantin JM, Mansoor O, Conio N, Schoeffler P. Effect of bronchial drainage on the improvement in gas exchange observed in ventral decubitus in ARDS. Ann Fr Anesth Reanim. 2000;19:156–163. doi: 10.1016/S0750-7658(00)00199-4.
    1. Galiatsou E, Kostanti E, Svarna E, Kitsakos A, Koulouras V, Efremidis SC, Nakos G. Prone position augments recruitment and prevents alveolar overinflation in acute lung injury. Am J Respir Crit Care Med. 2006;174:187–197. doi: 10.1164/rccm.200506-899OC.
    1. Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, Malacrida R, Di Giulio P, Fumagalli R, Pelosi P, Brazzi L, Latini R. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med. 2001;345:568–573. doi: 10.1056/NEJMoa010043.
    1. Guerin C, Gaillard S, Lemasson S, Ayzac L, Girard R, Beuret P, Palmier B, Le QV, Sirodot M, Rosselli S, Cadiergue V, Sainty JM, Barbe P, Combourieu E, Debatty D, Rouffineau J, Ezingeard E, Millet O, Guelon D, Rodriguez L, Martin O, Renault A, Sibille JP, Kaidomar M. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA. 2004;292:2379–2387. doi: 10.1001/jama.292.19.2379.
    1. Mancebo J, Fernández R, Blanch L, Rialp G, Gordo F, Ferrer M, Rodríguez F, Garro P, Ricart P, Vallverdú I, Gich I, Castaño J, Saura P, Domínguez G, Bonet A, Albert RK. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006;173:1233–1239. doi: 10.1164/rccm.200503-353OC.
    1. Sud S, Sud M, Friedrich JO, Adhikari NK. Effect of mechanical ventilation in the prone position on clinical outcomes in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. CMAJ. 2008;178:1153–1161. doi: 10.1503/cmaj.071802.
    1. Tiruvoipati R, Bangash M, Manktelow B, Peek GJ. Efficacy of prone ventilation in adult patients with acute respiratory failure: a meta-analysis. J Crit Care. 2008;23:101–110. doi: 10.1016/j.jcrc.2007.09.003.
    1. Alsaghir AH, Martin CM. Effect of prone positioning in patients with acute respiratory distress syndrome: a meta-analysis. Crit Care Med. 2008;36:603–609. doi: 10.1097/01.CCM.0000299739.98236.05.
    1. Kopterides P, Siempos II, Armaganidis A. Prone positioning in hypoxemic respiratory failure: meta-analysis of randomized controlled trials. J Crit Care. 2009;24:89–100. doi: 10.1016/j.jcrc.2007.12.014.
    1. Abroug F, Ouanes-Besbes L, Elatrous S, Brochard L. The effect of prone positioning in acute respiratory distress syndrome or acute lung injury: a meta-analysis. Areas of uncertainty and recommendations for research. Intensive Care Med. 2008;34:1002–1011. doi: 10.1007/s00134-008-1062-3.
    1. Sud S, Friedrich JO, Taccone P, Polli F, Adhikari NK, Latini R, Pesenti A, Guérin C, Mancebo J, Curley MA, Fernandez R, Chan MC, Beuret P, Voggenreiter G, Sud M, Tognoni G, Gattinoni L. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med. 2010;36:585–599. doi: 10.1007/s00134-009-1748-1.
    1. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–1367. doi: 10.1056/NEJMoa011300.
    1. van den Berghe G, Wilmer A, Hermans G, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–461. doi: 10.1056/NEJMoa052521.
    1. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–139. doi: 10.1056/NEJMoa070716.
    1. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–1297. doi: 10.1056/NEJMoa0810625.
    1. Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santré C, Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec'h C, Mayaux J, Lejeune J, Chevret S. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010;303:341–348. doi: 10.1001/jama.2010.516.
    1. Friedrich JO, Chant C, Adhikari NK. Does intensive insulin therapy really reduce mortality in critically ill surgical patients? A reanalysis of meta-analytic data. Crit Care. 2010;14:324. doi: 10.1186/cc9240.
    1. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S, Talmor D. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009;180:821–827. doi: 10.1503/cmaj.090206.
    1. Moghissi ES. Reexamining the evidence for inpatient glucose control: new recommendations for glycemic targets. Am J Health Syst Pharm. 2010;67:S3–S8. doi: 10.2146/ajhp100171.
    1. Standards of medical care in diabetes—2010Diabetes Care 2010,33(Suppl 1):S11-S61.
    1. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65. doi: 10.1016/0735-1097(95)00126-K.
    1. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med. 2007;35:2262–2267. doi: 10.1097/01.CCM.0000282073.98414.4B.
    1. Arabi YM, Tamim HM, Rishu AH. Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. Crit Care Med. 2009;37:2536–2544. doi: 10.1097/CCM.0b013e3181a381ad.
    1. Okabayashi T, Nishimori I, Yamashita K, Sugimoto T, Maeda H, Yatabe T, Kohsaki T, Kobayashi M, Hanazaki K. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. Arch Surg. 2009;144:933–937. doi: 10.1001/archsurg.2009.176.
    1. Okabayashi T, Nishimori I, Maeda H, Yamashita K, Yatabe T, Hanazaki K. Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: a prospective randomized clinical trial. Diabetes Care. 2009;32:1425–1427. doi: 10.2337/dc08-2107.
    1. Kanji S, Buffie J, Hutton B, Bunting PS, Singh A, McDonald K, Fergusson D, McIntyre LA, Hebert PC. Reliability of point-of-care testing for glucose measurement in critically ill adults. Crit Care Med. 2005;33:2778–2785. doi: 10.1097/01.CCM.0000189939.10881.60.
    1. Ghys T, Goedhuys W, Spincemaille K, Gorus F, Gerlo E. Plasma-equivalent glucose at the point-of-care: evaluation of Roche Accu-Chek Inform and Abbott Precision PCx glucose meters. Clin Chim Acta. 2007;386:63–68. doi: 10.1016/j.cca.2007.07.025.
    1. Fekih Hassen M, Ayed S, Gharbi R, Ben Sik Ali H, Marghli S, Elatrous S. Bedside capillary blood glucose measurements in critically ill patients: influence of catecholamine therapy. Diabetes Res Clin Pract. 2010;87:87–91. doi: 10.1016/j.diabres.2009.09.018.
    1. Kudsk KA, Croce MA, Fabian TC, Minard G, Tolley EA, Poret HA, Kuhl MR, Brown RO. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992;215:503–511. doi: 10.1097/00000658-199205000-00013.
    1. Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr. 2003;27:355–373. doi: 10.1177/0148607103027005355.
    1. Simpson F, Doig GS. Parenteral vs. enteral nutrition in the critically ill patient: a meta-analysis of trials using the intention to treat principle. Intensive Care Med. 2005;31:12–23. doi: 10.1007/s00134-004-2511-2.
    1. Peter JV, Moran JL, Phillips-Hughes J. A metaanalysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients. Crit Care Med. 2005;33:213–220. doi: 10.1097/01.CCM.0000150960.36228.C0.
    1. Villet S, Chiolero RL, Bollmann MD, Revelly JP, Cayeux RNMC, Delarue J, Berger MM. Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. Clin Nutr. 2005;24:502–509. doi: 10.1016/j.clnu.2005.03.006.
    1. Dvir D, Cohen J, Singer P. Computerized energy balance and complications in critically ill patients: an observational study. Clin Nutr. 2006;25:37–44. doi: 10.1016/j.clnu.2005.10.010.
    1. Pupelis G, Selga G, Austrums E, Kaminski A. Jejunal feeding, even when instituted late, improves outcomes in patients with severe pancreatitis and peritonitis. Nutrition. 2001;17:91–94. doi: 10.1016/S0899-9007(00)00508-6.
    1. Chuntrasakul C, Siltharm S, Chinswangwatanakul V, Pongprasobchai T, Chockvivatanavanit S, Bunnak A. Early nutritional support in severe traumatic patients. J Med Assoc Thai. 1996;79:21–26.
    1. Singh G, Ram RP, Khanna SK. Early postoperative enteral feeding in patients with nontraumatic intestinal perforation and peritonitis. J Am Coll Surg. 1998;187:142–146. doi: 10.1016/S1072-7515(98)00154-9.
    1. Kompan L, Vidmar G, Spindler-Vesel A, Pecar J. Is early enteral nutrition a risk factor for gastric intolerance and pneumonia? Clin Nutr. 2004;23:527–532. doi: 10.1016/j.clnu.2003.09.013.
    1. Nguyen NQ, Fraser RJ, Bryant LK, Burgstad C, Chapman MJ, Bellon M, Wishart J, Holloway RH, Horowitz M. The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and peptide YY concentrations in critically ill patients. Crit Care Med. 2008;36:1469–1474. doi: 10.1097/CCM.0b013e31816fc457.
    1. Doig GS, Heighes PT, Simpson F, Sweetman EA, Davies AR. Early enteral nutrition, provided within 24 h of injury or intensive care unit admission, significantly reduces mortality in critically ill patients: a meta-analysis of randomised controlled trials. Intensive Care Med. 2009;35:2018–2027. doi: 10.1007/s00134-009-1664-4.
    1. Doig GS, Heighes PT, Simpson F, Sweetman EA. Early enteral nutrition reduces mortality in trauma patients requiring intensive care: a meta-analysis of randomised controlled trials. Injury. 2011;42:50–56. doi: 10.1016/j.injury.2010.06.008.
    1. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264–2270. doi: 10.1097/00003246-200112000-00005.
    1. Khalid I, Doshi P, DiGiovine B. Early enteral nutrition and outcomes of critically ill patients treated with vasopressors and mechanical ventilation. Am J Crit Care. 2010;19:261–268. doi: 10.4037/ajcc2010197.
    1. Zaloga GP, Roberts PR, Marik P. Feeding the hemodynamically unstable patient: a critical evaluation of the evidence. Nutr Clin Pract. 2003;18:285–293. doi: 10.1177/0115426503018004285.
    1. Ibrahim EH, Mehringer L, Prentice D, Sherman G, Schaiff R, Fraser V, Kollef MH. Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. JPEN J Parenter Enteral Nutr. 2002;26:174–181. doi: 10.1177/0148607102026003174.
    1. Rice TW, Mogan S, Hays MA, Bernard GR, Jensen GL, Wheeler AP. Randomized trial of initial trophic versus full-energy enteral nutrition in mechanically ventilated patients with acute respiratory failure. Crit Care Med. 2011;39:967–974. doi: 10.1097/CCM.0b013e31820a905a.
    1. Taylor SJ, Fettes SB, Jewkes C, Nelson RJ. Prospective, randomized, controlled trial to determine the effect of early enhanced enteral nutrition on clinical outcome in mechanically ventilated patients suffering head injury. Crit Care Med. 1999;27:2525–2531. doi: 10.1097/00003246-199911000-00033.
    1. Dhaliwal R, Jurewitsch B, Harrietha D, Heyland DK. Combination enteral and parenteral nutrition in critically ill patients: harmful or beneficial? A systematic review of the evidence. Intensive Care Med. 2004;30:1666–1671. doi: 10.1007/s00134-004-2345-y.
    1. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365:506–517. doi: 10.1056/NEJMoa1102662.
    1. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008;34:1980–1990. doi: 10.1007/s00134-008-1213-6.
    1. Jones NE, Heyland DK. Pharmaconutrition: a new emerging paradigm. Curr Opin Gastorenterol. 2008;24:215–222. doi: 10.1097/MOG.0b013e3282f4cdd8.
    1. Beale RJ, Sherry T, Lei K, Campbell-Stephen L, McCook J, Smith J, Venetz W, Alteheld B, Stehle P, Schneider H. Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized controlled double-blind trial. Crit Care Med. 2008;36:131–144. doi: 10.1097/01.CCM.0000297954.45251.A9.
    1. Schneider A, Markowski A, Momma M, Seipt C, Luettig B, Hadem J, Wilhelmi M, Manns MP, Wedemeyer J. Tolerability and efficacy of a low-volume enteral supplement containing key nutrients in the critically ill. Clin Nutr. 2011;30:599–603. doi: 10.1016/j.clnu.2011.04.003.
    1. Avenell A. Hot topics in parenteral nutrition. Current evidence and ongoing trials on the use of glutamine in critically-ill patients undergoing surgery. Proc Nutr Soc. 2009;68:261–268. doi: 10.1017/S0029665109001372.
    1. Andrews PJ, Avenell A, Noble DW, Campbell MK, Battison CG, Croal BL, Simpson WG, Norrie J, Vale LD, Cook J, de Verteuil R, Milne AC. Randomised trial of glutamine and selenium supplemented parenteral nutrition for critically ill patients. Protocol Version 9, 19 February 2007 known as SIGNET (Scottish Intensive care Glutamine or seleNium Evaluative Trial) Trials. 2007;8:25. doi: 10.1186/1745-6215-8-25.
    1. Heyland DK, Dhaliwal R, Day AG, Muscedere J, Drover J, Suchner U, Cook D. REducing Deaths due to OXidative Stress (The REDOXS Study): rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patients. Proc Nutr Soc. 2006;65:250–263. doi: 10.1079/PNS2006505.
    1. Galbán C, Montejo JC, Mesejo A, Marco P, Celaya S, Sánchez-Segura JM, Farré M, Bryg DJ. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med. 2000;28:643–648. doi: 10.1097/00003246-200003000-00007.
    1. Dent DL, Heyland DK, Levy H. Immunonutrition may increase mortality in critically ill patients with pneumonia: results of a randomized trial. Crit Care Med. 2003;30:A17. doi: 10.1097/00003246-200212001-00063.
    1. Kieft H, Roos AN, van Drunen JD, Bindels AJ, Bindels JG, Hofman Z. Clinical outcome of immunonutrition in a heterogeneous intensive care population. Intensive Care Med. 2005;31:524–532. doi: 10.1007/s00134-005-2564-x.
    1. Caparrós T, Lopez J, Grau T. Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections and outcome. JPEN J Parenter Enteral Nutr. 2001;25:299–308. doi: 10.1177/0148607101025006299.
    1. Conejero R, Bonet A, Grau T, Esteban A, Mesejo A, Montejo JC, López J, Acosta JA. Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically ill patients with systemic inflammatory response syndrome: a randomized, single-blind, prospective, multicenter study. Nutrition. 2002;18:716–721. doi: 10.1016/S0899-9007(02)00847-X.
    1. Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34:2325–2333. doi: 10.1097/01.CCM.0000234033.65657.B6.
    1. Pontes-Arruda A, Martins LF, de Lima SM, Isola AM, Toledo D, Rezende E, Maia M, Magnan GB. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study. Crit Care. 2011;15:R144. doi: 10.1186/cc10267.
    1. Grau-Carmona T, Morán-García V, García-de-Lorenzo A, Heras-de-la-Calle G, Quesada-Bellver B, López-Martínez J, González-Fernández C, Montejo-González JC, Blesa-Malpica A, Albert-Bonamusa I, Bonet-Saris A, Herrero-Meseguer JI, Mesejo A, Acosta J. Effect of an enteral diet enriched with eicosapentaenoic acid, gamma-linolenic acid and anti-oxidants on the outcome of mechanically ventilated, critically ill, septic patients. Clin Nutr. 2011;30:578–584. doi: 10.1016/j.clnu.2011.03.004.
    1. Pontes-Arruda A, Hirasawa H. The effects of enteral feeding with eicosapentaenoic acid, γ-linolenic acid and antioxidant vitamins on mechanically ventilated patients with severe sepsis and septic shock: a retrospective analysis of Japanese-descendant patients. J Jpn Soc Intensive Care Med. 2011;18:207–213. doi: 10.3918/jsicm.18.207.
    1. Rice TW, Wheeler AP, Thompson BT, de Boisblanc BP, Steingrub J, Rock P. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306:1574–1581. doi: 10.1001/jama.2011.1435.
    1. Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF. The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients. Intensive Care Med. 1984;10:185–192. doi: 10.1007/BF00259435.
    1. Gastinne H, Wolff M, Delatour F, Faurisson F, Chevret S. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Study Group on Selective Decontamination of the Digestive Tract. N Engl J Med. 1992;326:594–599. doi: 10.1056/NEJM199202273260903.
    1. Hammond JM, Potgieter PD, Saunders GL, Forder AA. Double-blind study of selective decontamination of the digestive tract in intensive care. Lancet. 1992;340:5–9. doi: 10.1016/0140-6736(92)92422-C.
    1. de La Cal MA, Cerdá E, García-Hierro P, van Saene HK, Gómez-Santos D, Negro E, Lorente JA. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial. Ann Surg. 2005;241:424–430. doi: 10.1097/01.sla.0000154148.58154.d5.
    1. Pileggi C, Bianco A, Flotta D, Nobile CG, Pavia M. Prevention of ventilator-associated pneumonia, mortality and all intensive care unit acquired infections by topically applied anti-microbial or antiseptic agents: a meta-analysis of randomized controlled trials in intensive care units. Crit Care. 2011;15:R155. doi: 10.1186/cc10285.
    1. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ, Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF, Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw W, de Vries JW, Kaan JA, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009;360:20–31. doi: 10.1056/NEJMoa0800394.
    1. Silvestri L, van Saene HK, Milanese M, Gregori D, Gullo A. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect. 2007;65:187–203. doi: 10.1016/j.jhin.2006.10.014.
    1. Lingnau W, Berger J, Javorsky F, Fille M, Allerberger F, Benzer H. Changing bacterial ecology during a five-year period of selective intestinal decontamination. J Hosp Infect. 1998;39:195–206. doi: 10.1016/S0195-6701(98)90258-4.
    1. Oostdijk EA, de Smet AM, Blok HE, Thieme Groen ES, van Asselt GJ, Benus RF, Bernards SA, Frénay IH, Jansz AR, de Jongh BM, Kaan JA, Leverstein-van Hall MA, Mascini EM, Pauw W, Sturm PD, Thijsen SF, Kluytmans JA, Bonten MJ. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med. 2010;181:452–457. doi: 10.1164/rccm.200908-1210OC.
    1. Al Naiemi N, Heddema ER, Bart A, de Jonge E, Vandenbroucke-Grauls CM, Savelkoul PH, Duim B. Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. J Antimicrob Chemother. 2006;58:853–856. doi: 10.1093/jac/dkl316.
    1. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27:723–732. doi: 10.1097/00003246-199904000-00025.
    1. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645–650. doi: 10.1097/00003246-199804000-00010.
    1. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–124. doi: 10.1056/NEJMoa071366.
    1. Moran JL, Graham PL, Rockliff S, Bersten AD. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Crit Care. 2010;14:R134. doi: 10.1186/cc9182.
    1. Sherwin RL, Garcia AJ, Bilkovski R. Do low-dose cortico-steroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. J Emerg Med. 2012;43:7–12. doi: 10.1016/j.jemermed.2011.08.015.
    1. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, Keh D, Briegel J, Beishuizen A, Dimopoulou I, Tsagarakis S, Singer M, Chrousos GP, Zaloga G, Bokhari F, Vogeser M. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36:1937–1949. doi: 10.1097/CCM.0b013e31817603ba.
    1. Briegel J, Sprung CL, Annane D, Singer M, Keh D, Moreno R, Möhnle P, Weiss Y, Avidan A, Brunkhorst FM, Fiedler F, Vogeser M. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med. 2009;35:2151–2156. doi: 10.1007/s00134-009-1627-9.
    1. Allolio B, Dörr H, Stuttmann R, Knorr D, Engelhardt D, Winkelmann W. Effect of a single bolus of etomidate upon eight major corticosteroid hormone and plasma ACTH. Clin Endocrinol (Oxf) 1985;22:281–286. doi: 10.1111/j.1365-2265.1985.tb03241.x.
    1. Bone RC, Fisher CJ, Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylpredonisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653–658. doi: 10.1056/NEJM198709103171101.
    1. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of sepsisN Engl J Med 1987, 317: 659-665.
    1. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301:2362–2375. doi: 10.1001/jama.2009.815.
    1. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R. Methylpredonisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954–963. doi: 10.1378/chest.06-2100.
    1. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trialJAMA 2010, 303: 341-348.
    1. Oppert M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005;33:2457–2464. doi: 10.1097/01.CCM.0000186370.78639.23.
    1. Yildiz O, Doganay M, Aygen B, Güven M, Keleştimur F, Tutuû A. Physiolocal-dose steroid therapy in sepsis. Crit Care. 2002;6:251–259. doi: 10.1186/cc1498.
    1. Keh D, Boehnke T, Weber-Carstens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512–520. doi: 10.1164/rccm.200205-446OC.
    1. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24–33. doi: 10.1111/j.1365-2141.2009.07600.x.
    1. Taylor FB, Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330.
    1. Maruyama I, Sakata Y, Wada H, Asakura E, Okajima K, Gando S, Iba T, Uchiba M, Uchiyama T, Eguchi Y, Okamoto K, Ogura S, Kawasugi K, Kushimoto S, Koike K, Koga S, Seki Y, Madoiwa S, Mayumi T. Japanese Society of Thrombosis Hemostasis/DOC subcommittee: expert consensus based evidence for the treatment of disseminated intravascular coagulation due to infection. Jap J Thromb Hemost. 2009;20:77–113. doi: 10.2491/jjsth.20.315.
    1. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, Sakata Y. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84:398–405. doi: 10.1532/IJH97.05190.
    1. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endoh S, Shimazaki S. Diagnostic criteria for disseminated intravascular coagulation (DIC) by the Japanese Association for Acute Medicine- a report of the prospective multicenter study. J Jpn Assoc Acute Med. 2005;16:188–202.
    1. Gando S, Wada H, Asakura H, Iba T, Eguchi Y, Okamoto K, Ohtomo Y, Kawasugi K, Koga S, Koseki K, Tsuji H, Mayumi T, Murata A, Nakagawa M, Endo S. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost. 2005;11:71–76. doi: 10.1177/107602960501100108.
    1. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625–631. doi: 10.1097/01.CCM.0000202209.42491.38.
    1. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Car Med. 2008;36:145–150. doi: 10.1097/01.CCM.0000295317.97245.2D.
    1. Nakagaw M, Tsuji H. Current trends in the diagnosis of disseminated intravascular coagulation in Japan: findings of questionnaire survey. Jpn J Clin Hematol. 1999;40:362–364.
    1. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995;74:848–852.
    1. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6–11. doi: 10.1016/j.thromres.2009.08.017.
    1. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41. doi: 10.1111/j.1538-7836.2006.02267.x.
    1. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–1878. doi: 10.1001/jama.286.15.1869.
    1. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)–a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993;72:475–500. doi: 10.1016/0049-3848(93)90109-2.
    1. Yasunaga K, Ogawa N, Mori K, Aoki N, Matsuda T, Nakagawa M, Kakisita E, Kuramoto J, Maruyama I. Evaluation of clinical effect of danaparoid sodium (KB-101) on disseminated intravascular coagulation (DIC): double blind comparative study. Jpn Pharmacol Ther. 1995;23:2815–2834.
    1. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90–97. doi: 10.1111/j.1538-7836.2005.01697.x.
    1. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34:285–292. doi: 10.1097/01.CCM.0000194731.08896.99.
    1. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24:1374–1383. doi: 10.1161/01.ATV.0000134298.25489.92.
    1. Higuchi T, Nakamura T, Kakutani H, Ishii H. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor. Biol Pharm Bull. 2009;32:179–185. doi: 10.1248/bpb.32.179.
    1. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, Maruyama I. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol. 2008;28:1825–1830. doi: 10.1161/ATVBAHA.107.150631.
    1. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15:R123. doi: 10.1186/cc10228.
    1. Nishiyama T, Matsukawa T, Hanaoka K. Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation? Crit Care Med. 2000;28:1419–1422. doi: 10.1097/00003246-200005000-00027.
    1. Hsu JT, Chen HM, Chiu DF, Chen JC, Huang CJ, Hwang TL, Jan YY, Chen MF. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc. 2004;103:678–684.
    1. Kosaki G, Kambayashi J, Hirayama A, Mori K, Uchida T, Abe T, Matsuda M, Nagoya K, Terada H, Kanayama M, Fukutake K, Toyama K, Baba H, Shiba T, Igarashi N, Koie K, Kamiya T, Ishizaki T, Taenaka N, Kumon K, Katsurada K, Kataoka T, Aoki E, Isobe J, Kuramoto J, Osato K, Takeda S, Ichimaru M, Kuriyama K, Abe T, et al. A study on the effects of FOY on DIC – multicenter comparative clinical study. J Clin Exp Med (IGAKU NO AYUMI) 1983;124:144–154.
    1. Shibata A, Takahashi H, Aoki N, Matsuda T, Yasunaga K, Kondo M, Matsuda M, Hattori A, Kobayashi N, Ogawa N, Kawakami Y, Miyazaki T, Hirayama A, Yoshida Y, Chiba Y, Okamoto K, Tanabe K, Kanazawa T, Aizawa M, Kawabe H, Oumi T, Miura R, Mori K, Karigome S, Maekawa T, Yashiro K, Takeuchi H, Takeuchi S, Shimano S, Miyao S, et al. Treatment effects of FUT-175 on disseminated intravascular coagulation (DIC) – evaluation by multicenter comparative clinical study. Jap J Clin Exper Med (RINSHO TO KENKYU) 1988;65:921–940.
    1. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective randomized trial. Crit Care Med. 2002;30:2205–2211. doi: 10.1097/00003246-200210000-00005.
    1. Sugahara S, Suzuki H. Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodial Int. 2004;8:320–325. doi: 10.1111/j.1492-7535.2004.80404.x.
    1. Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, Chertow GM. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2006;1:915–919. doi: 10.2215/CJN.01430406.
    1. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care. 2009;24:129–140. doi: 10.1016/j.jcrc.2007.12.017.
    1. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74. doi: 10.1186/cc6916.
    1. Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jaber BL. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. Am J Kidney Dis. 2008;52:272–284. doi: 10.1053/j.ajkd.2008.02.371.
    1. Karvellas CJ, Farhat MR, Sajjad I, Mogensen SS, Leung AA, Wald R, Bagshaw SM. A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care. 2011;15:R72. doi: 10.1186/cc10061.
    1. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–1638. doi: 10.1056/NEJMoa0902413.
    1. Palevsky PM. Renal support in acute kidney injury–how much is enough? N Engl J Med. 2009;361:1699–1701. doi: 10.1056/NEJMe0907831.
    1. Vinsonneau C, Camus C, Combes A, de Beauregard MAC, Klouche K, Boulain T, Pallot JL, Chiche JD, Taupin P, Landais P, Dhainaut JF. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomized trial. Lancet. 2006;368:379–385. doi: 10.1016/S0140-6736(06)69111-3.
    1. Lins RL, Elseviers MM, Van der Niepen P, Hoste E, Malbrain ML, Damas P, Devriendt J. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant. 2009;24:512–518. doi: 10.1093/ndt/gfn560.
    1. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int. 2001;60:1154–1163. doi: 10.1046/j.1523-1755.2001.0600031154.x.
    1. Gasparović V, Filipović-Grcić I, Merkler M, Pisl Z. Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) - what is the procedure of choice in critically ill patients? Ren Fail. 2003;25:855–862. doi: 10.1081/JDI-120024300.
    1. Uehlinger DE, Jakob SM, Ferrari P, Eichelberger M, Huynh-Do U, Marti HP, Mohaupt MG, Vogt B, Rothen HU, Regli B, Takala J, Frey FJ. Comparison of continuous and intermittent renal replacement therapy for acute renal failure. Nephrol Dial Transplant. 2005;20:1630–1637. doi: 10.1093/ndt/gfh880.
    1. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. Am J Kidney Dis. 2004;44:1000–1007. doi: 10.1053/j.ajkd.2004.08.022.
    1. John S, Griesbach D, Baumgärtel M, Weihprecht H, Schmieder RE, Geiger H. Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant. 2001;16:320–327. doi: 10.1093/ndt/16.2.320.
    1. Uchino S, Bellomo R, Kellum JA, Morimatsu H, Morgera S, Schetz MR, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-Van Straaten HM, Ronco C. Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007;30:281–292.
    1. Bell M, SWING, Granath F, Schön S, Ekbom A, Martling CR. Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med. 2007;33:773–780. doi: 10.1007/s00134-007-0590-6.
    1. Chanard J, Wynckel A, Rieu P. Renal replacement therapy in acute renal failure. Lancet. 2006;368:1491. doi: 10.1016/S0140-6736(06)69628-1.
    1. Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008;36:610–617. doi: 10.1097/01.CCM.0B013E3181611F552.
    1. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA. 2008;299:793–805. doi: 10.1001/jama.299.7.793.
    1. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–427. doi: 10.1038/ki.2009.159.
    1. Fieghen HE, Friedrich JO, Burns KE, Nisenbaum R, Adhikari NK, Hladunewich MA, Lapinsky SE, Richardson RM, Wald R. The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol. 2010;11:32. doi: 10.1186/1471-2369-11-32.
    1. Kaizu K, Inada Y, Kawamura A, Oda S, Hirasawa H. Current status of blood purification in critical care in Japan. Contrib Nephrol. 2010;166:4–10. doi: 10.1159/000314844.
    1. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30. doi: 10.1016/S0140-6736(00)02430-2.
    1. Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T, Martin PY. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006;70:1312–1317. doi: 10.1038/sj.ki.5001705.
    1. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 2008;19:1233–1238. doi: 10.1681/ASN.2007111173.
    1. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20. doi: 10.1056/NEJMoa0802639.
    1. Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen J. Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant. 2012;27:967–973. doi: 10.1093/ndt/gfr486.
    1. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002;346:305–310. doi: 10.1056/NEJMoa010877.
    1. Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D, Kielstein JT. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant. 2009;24:2179–2186. doi: 10.1093/ndt/gfp035.
    1. Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med. 2010;38:1360–1369. doi: 10.1097/CCM.0b013e3181d9d912.
    1. Jun M, Heerspink HJ, Ninomiya T, Gallagher M, Bellomo R, Myburgh J, Finfer S, Palevsky PM, Kellum JA, Perkovic V, Cass A. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2010;5:956–963. doi: 10.2215/CJN.09111209.
    1. Zhang H, Xu X, Zhu H. Intensive- vs less-intensive-dose continuous renal replacement therapy for the intensive care unit-related acute kidney injury: a meta-analysis and systematic review. J Crit Care. 2010;25:595–600. doi: 10.1016/j.jcrc.2010.05.030.
    1. Latour-Pérez J, Palencia-Herrejón E, Gómez-Tello V, Baeza-Román A, García-García MA, Sánchez-Artola B. Intensity of continuous renal replacement therapies in patients with severe sepsis and septic shock: a systematic review and meta-analysis. Anaesth Intensive Care. 2011;39:373–383.
    1. Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med. 2010;181:1128–1155. doi: 10.1164/rccm.200711-1664ST.
    1. Ghani RA, Zainudin S, Ctkong N, Rahman AF, Wafa SR, Mohamad M, Manaf MR, Ismail R. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton) 2006;11:386–393. doi: 10.1111/j.1440-1797.2006.00600.x.
    1. Boussekey N, Chiche A, Faure K, Devos P, Guery B, d'Escrivan T, Georges H, Leroy O. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med. 2008;34:1646–1653. doi: 10.1007/s00134-008-1127-3.
    1. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001;27:978–986. doi: 10.1007/s001340100963.
    1. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 2002;30:100–106. doi: 10.1097/00003246-200201000-00016.
    1. Peng Z, Pai P, Hong-Bao L, Rong L, Han-Min W, Chen H. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients. Cytokine. 2010;50:186–191. doi: 10.1016/j.cyto.2010.02.005.
    1. Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns. 2005;31:623–628. doi: 10.1016/j.burns.2005.02.004.
    1. Peng Z, Pai P, Han-Min W, Jun Z, Hong-Bao L, Rong L, Chen H. Evaluation of the effects of pulse high-volume hemofiltration in patients with severe sepsis: a preliminary study. Int J Artif Organs. 2010;33:505–511.
    1. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009;37:803–810. doi: 10.1097/CCM.0b013e3181962316.
    1. de Pont AC. Hemofiltration in the early phase of sepsis: friend or foe? Crit Care Med. 2009;37:1125–1126. doi: 10.1097/CCM.0b013e3181987d2d.
    1. Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis. 2007;50:296–304. doi: 10.1053/j.ajkd.2007.05.003.
    1. Oda S, Sadahiro T, Hirayama Y, Nakamura M, Watanabe E, Tateishi Y, Hirasawa H. Non-renal indications for continuous renal replacement therapy: current status in Japan. Contrib Nephrol. 2010;166:47–53. doi: 10.1159/000314851.
    1. Joannes-Boyau O, Honore PM, Boer W, Collin V. Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation? Nephrol Dial Transplant. 2009;24:354–357. doi: 10.1093/ndt/gfn666.
    1. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23:400–405. doi: 10.1097/01.shk.0000159930.87737.8a.
    1. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–2452. doi: 10.1001/jama.2009.856.
    1. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. doi: 10.1186/cc5780.
    1. Vincent JL. Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA. 2009;302:1968–1970. doi: 10.1001/jama.2009.1606.
    1. Iwasaki E, Tokioka H, Fukushima T, Mikane T, Oku S, Kobayashi H, Ihii M. Improved outcome of septic shock patients treated without polymyxin B hemoperfusion. J Jpn Assoc Acute Med. 2012;23:92–100.
    1. Tsujimoto H, Ono S, Hiraki S, Majima T, Kawarabayashi N, Sugasawa H, Kinoshita M, Hiraide H, Mochizuki H. Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock. J Endotoxin Res. 2004;10:229–237.
    1. Hirasawa H. Indications for blood purification in critical care. Contrib Nephrol. 2010;166:21–30. doi: 10.1159/000314847.
    1. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233–245. doi: 10.1007/s10875-007-9088-9.
    1. Nimmerjahn F, Ravetch JV. Anti- inflammatory actions of intravenous immunoglobulin. Ann Rev Immunol. 2008;26:512–533. doi: 10.1146/annurev.immunol.26.021607.090232.
    1. Venet F, Gebeile R, Bancel J, Guignant C, Poitevin-Later F, Malcus C, Lepape A, Monneret G. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol. 2011;11:2086–2090. doi: 10.1016/j.intimp.2011.08.024.
    1. Taccone FS, Stordeur P, De Becker D, Creteur J, Vincent JL. Gamma-globulin levels in patients with community-acquired septic shock. Shock. 2009;32:379–385. doi: 10.1097/SHK.0b013e3181a2c0b2.
    1. Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23:298–304. doi: 10.1097/01.shk.0000157302.69125.f8.
    1. Masaoka T, Hasegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, Urabe A, Shibata A, Saito H, Okuma M, Horiuchi A, Saito Y, Ozawa K, Usami M, Ohashi Y. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother. 2000;48:199–217.
    1. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind placebo-controlled trial. Clin Infect Dis. 2003;37:333–340. doi: 10.1086/376630.
    1. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Ubelacker R, Buchheidt D, Behre G, Hiddemann W, Schiel X. IgMA-enriched immunoglobulin neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34:1319–1325. doi: 10.1097/01.CCM.0000215452.84291.C6.
    1. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Müller-Werdan U. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35:2693–2701. doi: 10.1097/01.CCM.0000295426.37471.79.
    1. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090.
    1. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39:38–46. doi: 10.1086/421089.
    1. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hébert PC. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Int Med. 2007;146:193–203. doi: 10.7326/0003-4819-146-3-200702060-00009.
    1. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677–2685. doi: 10.1097/01.CCM.0000295263.12774.97.
    1. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35:2686–2692. doi: 10.1097/01.CCM.0000295312.13466.1C.
    1. Alejandria MM, Lansang MAD, Dans LF, Mantaring JB., III Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;9:CD001090.
    1. Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, Tartamella F, Prisco L, Bigotto F, Bigolin T, Ferluga M, Batticci I, Michelone E, Borelli M, Viviani M, Tomasini A. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27:167–171. doi: 10.1016/j.jcrc.2011.05.012.
    1. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255(Suppl 3):3–6. doi: 10.1007/s00415-008-3002-0.
    1. Tamakuma S, Koseki K, Ohtsuka T. Clinical study of MR-20 on patients in shock. J Jpn Assoc Acute Med. 1984;8:619–624.
    1. Yamamura H, Tamakuma S, Nakajima M. Clinical evaluation of MR-20 on various shock patients - multicenter double-blind controlled trial with aprotinin as a control. J Clin Exp Med (IGAKU NO AYUMI) 1984;129:730–738.
    1. Yoshida N, Yoshikawa T, Tanigawa T, Miyagawa H, Sugino S, Kondo M. The effects of protease inhibitors on CLA (Cypridina Luciferin Analog) dependent chemiluminescence from human polymorphonuclear leukocytes. J Clin Exp Med (IGAKU NO AYUMI) 1987;140:765–766.
    1. Chen H, He MY, Li YM. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha 1: a prospective, randomized, controlled pilot study. Chin Med J (Engl) 2009;122:883–888.
    1. Huang SW, Chen J, Ouyang B, Yang CH, Chen MY, Guan XD. Immunotherapy improves immune homeostasis and increases survival rate of septic patients. Chin J Traumatol. 2009;12:344–349.
    1. Li Y, Chen H, Li X, Zhou W, He M, Chiriva-Internati M, Wachtel MS, Frezza EE. A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin {alpha} 1. J Intensive Care Med. 2009;24:47–53.
    1. Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY, Praseedom RK. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis. 2008;198:723–730. doi: 10.1086/590500.
    1. Zeiher BG, Artigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT, Bernard G. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695–1702. doi: 10.1097/01.CCM.0000133332.48386.85.
    1. Hayakawa M, Katabami K, Wada T, Sugano M, Hoshino H, Sawamura A, Gando S. Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock. 2010;33:14–18. doi: 10.1097/SHK.0b013e3181aa95c4.
    1. Rinka H, Yoshimoto A, Matsuura Y, Miyaichi T, Kan M, Kaji A, Miyamoto S. Neutrophil elastase inhibitor improves the vascular permeability in patients with sepsis induced ALI/ARDS. J Jpn Assoc Acute Med. 2007;18:283–290.
    1. Sato N, Imai S, Yaegashi S, Kojika M, Makabe H, Abe H, Onodera M, Fujino Y, Inoue Y, Kitamura M, Endo S. Effects of Elaspol on septic acute lung injury (ALI) Prog Med. 2003;23:915–919.
    1. Tamakuma S, Shiba T, Hirasawa H, Kubota T. Evaluation of efficacy and safety of neutrophil elastase inhibitor, ONO-5046Na on acute lung injury complicated with systemic inflammatory response syndrome. J Clin Therap Med. 1998;14:289–318.
    1. Aikawa N, Ishizaka A, Hirasawa H, Shimazaki S, Yamamoto Y, Sugimoto H, Shinozaki M, Taenaka N, Endo S, Ikeda T, Kawasaki Y. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011;24:549–554. doi: 10.1016/j.pupt.2011.03.001.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe